Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Published:2024-05 Issue:5 Volume:25 Page:614-625
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fehm Tanja,Cottone Francesco,Dunton Kyle,André Fabrice,Krop Ian,Park Yeon Hee,De Laurentiis Michelino,Miyoshi Yasuo,Armstrong Anne,Borrego Manuel Ruiz,Yerushalmi Rinat,Duhoux Francois P,Takano Toshimi,Lu Wenjing,Egorov Anton,Kim Sung-Bae

Publisher

Elsevier BV

Reference26 articles.

1. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

2. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

3. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;Modi;N Engl J Med,2020

4. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival;Onitilo;Clin Med Res,2009

5. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond;Perez;Expert Opin Biol Ther,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention;International Immunopharmacology;2024-09

2. A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B);Annals of Oncology;2024-09

3. Genetic factors in the pathogenesis of cardio-oncology;Journal of Translational Medicine;2024-08-05

4. Trastuzumab-Deruxtecan beim HER2-positiven metastasierten Mammakarzinom;Geburtshilfe und Frauenheilkunde;2024-08